Evidence map›Paper›PMID 38285118›Full record

ArticleDiscover oncology2024

Construction and in vitro evaluation of pH-sensitive nanoparticles to reverse drug resistance of breast cancer stem cells.

Weinan Li, Yuhan Fu, Jialin Sun, Hexin Gong, Ru Yan, Yanhong Wang

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Evaluation of hepatic cancer stem cells (CDMolecular biology reports · 2025
    Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Weinan Li *School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China. tyler2046@163.com.
Yuhan Fu *School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
Jialin SunPostdoctoral Research Station, Heilongjiang University of Chinese Medicine, Harbin, China.
Hexin GongSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
Ru YanSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
Yanhong WangSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China. wang.yanhong@163.com.
Heilongjiang University of Chinese Medicine · CN

Funding

Heilongjiang University of Chinese Medicine graduate innovative research project No. 2023yjscx011National Natural Science Foundation of China No. 82074025Science Foundation Project of Heilongjiang Province of China No. LH2021H098Self-funded Project of Science and Technology Plan of Harbin Science and Technology Bureau No. 2022ZCZJNS049
6 · The paper itself

Abstract

Breast cancer is a major threat to safety and health of women. The breast cancer stem cells (BCSCs) have multi-drug resistance to chemotherapy drugs, which leads to chemotherapy failure. We proposed a strategy of delivery of tumor-killing drugs and a resistance reversal agent, to enhance inhibition of BCSCs. Here, schisandrin B (SchB)/AP NPs are constructed using acid-grafted-poly (β-amino ester) (ATRA-g-PBAE, AP) grafted polymer nanoparticle encapsulated SchB, with pH-sensitive release function. This drug delivery system has good pharmacological properties and can increase the SchB release with the decrease of pH. The NPs showed cytotoxic effects in reversing ATRA resistance to BCSCs. Lysosomal escape was achieved when the nanoparticles were taken up by BCSCs. In addition, we found that NPs may reverse MDR by inhibiting the expression of P-glycoprotein (P-gp) and affecting the energy supply of drug efflux. This study provides a nanodelivery therapy strategy that reverses BCSCs multidrug resistance (MDR) and demonstrates that it did so by interfering with cancer cell energy metabolism. Therefore, the co-delivery strategy of ATRA and SchB provides a new option for the treatment of breast cancer.

Indexed as

Breast cancer stem cellsMultidrug resistanceNanoparticlesP-glycoproteinpH-sensitive

Identifiers

PMID38285118
PMCPMC10825093
OpenAlexW4391323500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.